Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


ONcology Rounds


 

Cancer Moonshot


Jennifer Pietenpol

As part of the national Cancer Moonshot initiative, a Blue Ribbon Panel (BRP) of 28 cancer leaders, including Vanderbilt-Ingram Cancer Center (VICC) director Jennifer Pietenpol, PhD, has delivered a series of recommendations to accelerate the pace of cancer prevention efforts and scientific discovery. The BRP recommended 10 scientific approaches most likely to make a decade's worth of progress against cancer in five years.

The report was delivered last month to the National Cancer Advisory Board (NCAB) whose members voted to accept the recommendations with some revisions. The National Cancer Institute's acting director also accepted the recommendations.


Scott Hiebert

Pietenpol, who served as co-leader of a working group on Precision, Prevention and Early Detection, was one of two VICC leaders deeply involved in this initiative. Scott Hiebert, PhD, Hortense B. Ingram Professor of Cancer Research and associate director of Basic Research and of Shared Resources at VICC, was recently appointed by President Obama to serve on the NCAB and voted in favor of the recommendations.

"These recommendations cut across disciplines and address crucially important issues like scientific discovery to better understand the mechanisms that lead to resistance to therapy, differences between adult and pediatric cancer, and data sharing at a national level," said Hiebert.

The 10 transformative approaches are:

  • Engage patients to contribute their tumor profile data to expand knowledge about which therapies work in specific populations.
  • Establish a cancer immunotherapy clinical trials network.
  • Identify therapeutic targets to overcome drug resistance.
  • Create a national ecosystem for sharing and analyzing cancer data.
  • Improve the understanding of fusion oncoproteins in pediatric cancer.
  • Accelerate the development of guidelines for monitoring and management of patient symptoms to minimize side effects of therapy.
  • Reduce cancer risk and health disparities through prevention strategies.
  • Predict response to treatments through retrospective analysis of patient specimens.
  • Create 3-D maps of human tumor evolution to document the evolution from a precancerous lesion to advanced cancer.
  • Develop new cancer technologies to characterize tumors and test therapies.

In addition to the 10 approaches, the scientific road map includes some demonstration projects: enhanced testing for Lynch syndrome, an inherited condition that increases the risk for several cancers; the establishment of a nationwide pediatric immunotherapy clinical trials network; and a project focused on the pipeline of emergent therapies with the goal of improving precision therapy.

The entire report can be viewed at cancer.gov/brp.

VUMC First to Use New Therapy in Prostate Cancer Clinical Trial

Vanderbilt University Medical Center is the world's first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation.


David Penson, MD

Investigators, David Penson, MD, MPH, professor and chair of Urologic Surgery, and Sandeep Arora, MBBS, assistant professor of Radiology and Radiological Sciences, treated the first patient on Sept. 21 in Nashville. Multiple sites throughout the U.S., Germany, Netherlands, Spain and Canada will also be participating in TACT, a prospective, single-arm pivotal clinical study of 110 patients to further evaluate the safety and efficacy of TULSA-PRO.

Penson said the Vanderbilt research is a joint effort between Urology, Radiology and the Vanderbilt University Institute of Imaging Science (VUIIS). "Enrolling the first patient in this trial is truly exciting for our institution. We recognize the potential value that TULSA provides to the clinical community to address the unmet needs associated with current prostate cancer treatments," Penson said.

Prostate cancer is the second most common cancer among men, and patients often experience side effects such as erectile dysfunction, urinary incontinence and bowel complications. The results of a previous Phase 1 clinical study for TULSA-PRO, published in the September 2016 issue of European Urology, showed accurate ablation of targeted prostate tissue with minor impact on urinary, erectile and bowel function at 12 months.

UTHSC Studies Pancreatic Cancer


Dr. Chauhan & Team

Subhash C. Chauhan, PhD, a professor in the Departments of Pharmaceutical Sciences and Pathology in the UTHSC Colleges of Pharmacy and Medicine at the University of Tennessee Health Science Center (UTHSC), has received two grants totaling $3.4 million to develop targeted nanomedicine for pancreatic cancer, the fourth leading cause of cancer-related deaths in the United States.

Pancreatic cancer currently is very difficult to manage because there is a lack of therapeutic treatment options, and survival rates are low because of poor drug delivery and chemotherapy resistance that occurs as a result of excessive fibrosis and connective tissue growth in pancreatic tumors.

"Our goal with these projects is to develop effective treatments and increase the effectiveness of the currently used medication, Gemcitabine," said Chauhan.

Small Cell Lung Cancer Award

Jonathan Lehman, MD, PhD, instructor in Medicine in the Division of Hematology/Oncology at Vanderbilt-Ingram Cancer Center (VICC), has been named one of only three early career researchers to receive a 2016 Career Development Award from LUNGevity. The award from the nonprofit organization - which provides support programs for lung cancer patients and families, as well as funding for innovative scientific research - will provide support for Lehman's research on small cell lung cancer (SCLC), the most aggressive and deadly form of the disease. SCLC represents approximately 15 percent of all lung cancers, is responsible for more than 30,000 deaths in the U.S. and 200,000 worldwide annually, and has a five-year survival of less than 7 percent. Lehman is studying how SCLC becomes resistant to therapy.


Jonathan Lehman, MD, PhD

"Our preliminary data has identified multiple novel subpopulations of cells in small cell lung cancer. We are working to better characterize this diversity by using a novel technique that can identify levels of more than 40 different cell surface markers simultaneously in individual cells. This will give us a signaling and surface marker map," Lehman explained.

He and his colleagues will then compare this newly created "map" with those from human tumors grown in an animal model before and after chemotherapy treatment to determine how these tumors change with treatment. They also will test new treatments based on destroying or disrupting specific subpopulations of cells in order to interfere with cancer growth, potentially leading to new, more targeted treatment strategies for SCLC.


WEB:

VICC

UTHSC

 
Share:

Related Articles:


Recent Articles

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Read More

DRUG COMPANIES URGED TO PROVIDE DISCOUNTS TO 340B COMMUNITY PHARMACIES

Yesterday, counsel for the American Hospital Association and the five other national groups and three individual hospital systems that sued the Department of Health and Human Services (HHS) over its failure to halt drug company actions that undermine the 340B drug pricing program sent letters demanding that the offending drug companies immediately halt their illegal activities.

Read More

Study Shows Drastic Increases in Opioid-Affected Births

The rate of mothers who had an opioid-related diagnosis when delivering their baby increased by 131% from 2010-2017, as the incidence of babies diagnosed with drug withdrawal, known as neonatal abstinence syndrome (NAS), increased by 82% nationally during that same time period.

Read More

Case Management: Enhancing Revenue, Care Transitions and Patient Outcomes throughout the Hospital System

The importance of hospital and health system case management has grown exponentially over the past 10 years and is now getting attention from leaders throughout the healthcare industry.

Read More

TennCare Block Grant Waiver Approved

More than a year after submitting Amendment 42 to the Centers for Medicare and Medicaid Services (CMS) requesting a waiver to increase flexibility in the administration of the state's Medicaid program, Tennessee has received an affirmative nod to move forward.

Read More

OptumInsight and Change Healthcare Combine to Advance a More Modern, Information and Technology-Enabled Health Care Platform

Accelerates work to improve outcomes and experiences and lower the cost of health care

Read More

AHA Statement On Dc Circuit Court Of Appeals Decision On Mandated Disclosure Of Negotiated Rates

Read More

AHA STATEMENT ON COURT DELAY OF MOST FAVORED NATION MODEL INTERIM FINAL RULE

Read More

Sen. Alexander's Farewell Address

Read More

Alexander: Congress Set to End Surprise Medical Billing

Proposal to protect patients from surprise medical bills and resolve payment disputes between providers and insurers included in government funding legislation that the Congress will vote on this week

Read More

Email Print
 
 

 

 


Tags:
Cancer, Cancer Moonshot, David Penson, Jennifer Pietenpol, Jonathan Lehman, Oncology, Pancreatic Cancer, Prostate Cancer, Sandeep Arora, Scott Hiebert, Subhash C. Chauhan, TULSA-PRO Ablation Clinical Trial, University of Tennessee Health Science Center, UTHSC, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, VICC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: